

Histopathological Diagnosis amongst Subjects of Liver Diseases Reporting to the Pathology Department at a Tertiary Care Centre

Dhanraj Sarda

Associate Professor, Department of Pathology, Hi-Tech Medical College & Hospital, Rourkela, Odisha, India.

ABSTRACT

Background: Chronic liver diseases are one of the greatest cause death around the world, representing around 1.03 million deaths each year. The aim of the present study was to evaluate the histopathological diagnosis of subjects with liver disease.

Materials and Methods: The present study was conducted in a prospective fashion enrolling 120 subjects reporting to the Department of Pathology, Hi-Tech Medical College & Hospital, Rourkela, Odisha (India) with liver disorders. There were 60 cases of hepatitis either viral or non-viral and 60 cases of cirrhosis of mixed etiology. All the data thus obtained was arranged in a tabulated form and analyzed using SPSS software. Percentage and frequency distribution were used to describe the results.

Results: The present study enrolled 120 subjects, out of these 80 were males and 40 were females. The mean age of the study population was 40.23+/- 7.89 years. Ductopenia was shown by single subject of liver cirrhosis. Blood stasis was observed by 3.3% liver cirrhosis and 1.7% hepatitis subjects. Focal type of necrosis was seen amongst 68.3% (n=41) liver

cirrhosis subjects and 73.3% (n=44) hepatitis subjects. Inflammatory infiltrate was seen amongst 36.7% (n=22) liver cirrhosis subjects and 16.7% (n=10) chronic hepatitis subjects.

Conclusion: In present study; portal inflammation was most common mesenchymal change in liver cirrhosis and hepatitis. Focal type of necrosis was seen in both the cases.

Keywords: Hepatic, Inflammation, Mesenchymal.

*Correspondence to:

Dr. Dhanraj Sarda,
Associate Professor,
Department of Pathology,
Hi-Tech Medical College, Rourkela, Odisha, India.

Article History:

Received: 13-04-2018, Revised: 05-05-2018, Accepted: 29-05-2018

Access this article online

Website: www.ijmrp.com	Quick Response code 
DOI: 10.21276/ijmrp.2018.4.3.053	

INTRODUCTION

Liver disorders represent a crucial part of digestive disorders, that affect almost 12% of the population of our country.¹ Chronic liver diseases are one of the greatest cause death around the world, representing around 1.03 million deaths each year.^{2,3} Morbidities associated with chronic hepatic disorder has elevated in the last 30 years. This is due to more efficient and better possibilities for diagnosis in order to a decrease the age of subjects at the time of diagnosis of liver disorder and the increased cost of certain treatments, which require an exacting diagnosis of the pathology. The etio pathology of chronic liver disease is an associated interaction between various toxic factors like alcohol intake, viral factors and autoimmune factors.^{4,5} Alcohol is concerned in about more than 50% of liver associated deaths in the United States of America and complications of alcohol are responsible for quarter of million deaths annually.⁶

Alcohol abuse usually leads to three pathologically different liver diseases e.g. Fatty liver, alcoholic hepatitis and cirrhosis. They can also occur at the same time and in same patient.⁷ Fatty steatosis is a very frequent finding in biopsies and during post mortem examination of such patients. The involvement of liver cell

may be focal, diffuse, or zonal.⁸ The aim of the present study was to evaluate the histopathological diagnosis of subjects with liver disease.

MATERIALS AND METHODS

The present study was conducted in a prospective fashion enrolling 120 subjects reporting to the Department of Pathology, Hi-Tech Medical College & Hospital, Rourkela, Odisha (India) with liver disorders. There were 60 cases of hepatitis either viral or non-viral and 60 cases of cirrhosis of mixed etiology. All the subjects were informed about the study and a written consent was obtained from them in their vernacular language. The study was approved by the institute's ethical board. Puncture biopsy of liver using echo guided technique is used for obtaining the specimens. Fixation of the tissues was done in 8% formalin which was followed by embedding in paraffin block. 4 micrometer sections were cut and stained using H and E staining technique. GS trichrome staining was used to assess liver fibrosis. All the data thus obtained was arranged in a tabulated form and analyzed using SPSS software. Percentage and frequency distribution were used to describe the results.

RESULTS

The present study enrolled 120 subjects, out of these 80 were males and 40 were females. The mean age of the study population was 40.23+/- 7.89 years.

Table 1 shows the mesenchymal changes in liver cirrhosis and chronic hepatitis subjects. Ductopenia was shown by single subject of liver cirrhosis. Blood stasis was observed by 3.3% liver cirrhosis and 1.7% hepatitis subjects. There were 33.3% subjects with liver cirrhosis and 6.7% subjects with hepatitis that showed hyperplasia of canaliculi. Portal fibrosis was seen in 25% liver cirrhosis subjects and 73.3% chronic hepatitis subjects. Majority of subject i.e. 85% with cirrhosis and 90% with hepatitis had portal inflammation. Table 2 shows the type of necrosis amongst subjects of chronic hepatitis and cirrhosis. Focal type of necrosis

was seen amongst 68.3% (n=41) liver cirrhosis subjects and 73.3% (n=44) hepatitis subjects. Periportal type of necrosis was seen amongst 43.3% (n=26) liver cirrhosis subjects and 31.7% (n=19) hepatitis subjects. Periportal and bridging type of necrosis was seen amongst 11.7% (n=7) liver cirrhosis subjects and 11.7% (n=7) hepatitis subjects.

Table 3 shows the type of parenchymal lesions in chronic hepatitis and liver cirrhosis. Inflammatory infiltrate was seen amongst 36.7% (n=22) liver cirrhosis subjects and 16.7% (n=10) chronic hepatitis subjects. Necrosis was seen amongst 23.3% (n=14) liver cirrhosis subjects and 25% (n=15) chronic hepatitis subjects. Both were seen amongst 40% (n=24) liver cirrhosis subjects and 5.3% (n=35) chronic hepatitis subjects.

Table 1: Mesenchymal changes in liver cirrhosis and chronic hepatitis

Changes	Liver Cirrhosis	Chronic Hepatitis
Ductopenia	1(1.7%)	0
Blood stasis	2(3.3%)	1(1.7%)
Hyperplasia of canaliculi	20(33.3%)	4(6.7%)
Biliary stasis	2(3.3%)	2(3.3%)
Post portal fibrosis	25(41.7%)	9(15%)
Portal fibrosis	15(25%)	44(73.3%)
Portal inflammation	51(85%)	54(90%)


Table 2: Type of necrosis in chronic hepatitis and liver cirrhosis

Type	Liver Cirrhosis	Chronic Hepatitis
Focal	41(68.3%)	44(73.3%)
Periportal	26(43.3%)	19(31.7%)
Periportal and bridging	7(11.7%)	7(11.7%)

Table 3: The type of parenchymal lesions in chronic hepatitis and liver cirrhosis

Type	Liver Cirrhosis	Chronic Hepatitis
Inflammatory infiltrate	22(36.7%)	10(16.7%)
Necrosis	14(23.3%)	15(25%)
Both	24(40%)	35(5.3%)

Graph 1: Mesenchymal changes in liver cirrhosis and chronic hepatitis



DISCUSSION

Liver is susceptible to various metabolic, polymicrobial and circulatory trauma. In some cases, the disorder is primary while in some others the involvement of liver is secondary, which may be due to cardiac decompensation or extra hepatic infections. As per the study conducted by Ghosh CK et al⁹ the most common cause of hepatomegaly was liver abscess and it was most commonly due to amoebiasis, second to it was congestive cardiac failure. There were few cases of hepatitis and hepatocellular carcinoma also.

According to the study conducted Kringsholm B et al¹⁰ and Passarino G et al¹¹ chronic hepatitis was the second most frequent cause of liver disease. In our study, Focal type of necrosis was seen amongst 68.3% (n=41) liver cirrhosis subjects and 73.3% (n=44) hepatitis subjects. Periportal type of necrosis was seen amongst 43.3% (n=26) liver cirrhosis subjects and 31.7% (n=19) hepatitis subjects. Periportal and bridging type of necrosis was seen amongst 11.7% (n=7) liver cirrhosis subjects and 11.7% (n=7) hepatitis subjects. According to a study conducted by DAINA et al¹², mesenchymal changes and dystrophy were present in more than 90% of the patients, parenchymal alterations were seen in 85% of the subjects and fibrosis amongst 50% of the patients. The alterations thus observed was similar to study conducted by Craig et al, Łapiński et al and Walsh et al.¹³⁻¹⁵ Fibrosis of liver is generally seen in response to liver disorder independent of the etiology.¹⁶⁻¹⁸ Fibrosis of liver is because of synthesis and deposition of extracellular material that is rich in collagen secreted by fibroblasts and myofibroblasts of liver.¹⁹⁻²¹

As per our study, Ductopenia was shown by single subject of liver cirrhosis. Blood stasis was observed by 3.3% liver cirrhosis and 1.7% hepatitis subjects. There were 33.3% subjects with liver cirrhosis and 6.7% subjects with hepatitis that showed hyperplasia of canaliculi. Portal fibrosis was seen in 25% liver cirrhosis subjects and 73.3% chronic hepatitis subjects. Majority of subject i.e. 85% with cirrhosis and 90% with hepatitis had portal inflammation. Majority of studies have shown that chronic inflammation, is present in most chronic liver disorders (hepatitis, non-alcoholic steatohepatitis, autoimmune disorders of liver) and it is the major cause of fibrogenesis in liver.^{22,23} According to certain studies, perisinusoidal dendritic cells present the chief effective cells that responsible for the initiation of liver fibrosis.^{24,25} Untreated liver fibrosis proceeds into liver cirrhosis and high portal blood pressure with organ failure and death.^{26,27}

CONCLUSION

Liver diseases are very common in today's world. It has a multifactorial etiology. In present study; portal inflammation was most common mesenchymal change in liver cirrhosis and hepatitis. Focal type of necrosis was seen in both the cases.

REFERENCES

1. Saxena R, Zucker SD, Crawford JM. Anatomy and physiology of the liver. In: Zakim D, Boyer TD (eds). *Hepatology: a textbook of liver disease*. 4th edition, Saunders, Philadelphia, 2003,3–30.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis

- for the Global Burden of Disease Study 2010. *Lancet*, 2012, 380(9859):2095–0128.
3. Fernández-Iglesias A, Gracia-Sancho J. How to face chronic liver disease: the sinusoidal perspective. *Front Med (Lausanne)*, 2017, 4:7.
4. Aizawa Y, Hokari A. Autoimmune hepatitis: current challenges and future prospects. *Clin Exp Gastroenterol*, 2017, 10:9–18.
5. Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic- fatty liver disease. *PLoS One*, 2013, 8:e58895.
6. Shah VS. Alcoholic Liver Disease. In: Hauser S, editors. *Mayo Clinic Gastroenterology and Hepatology Broad Review*. 4th ed. New York: Oxford University Press; 2011.p 295-303.
7. Bal MS, Singh SP, Bodal VK, Oberoi SS, Surinder K. Pathological findings in liver autopsy. *Journal of Indian Academy of Forensic Medicine* 2004; 26(2):971-73.
8. Sotoudehmanesh R, Sotoudeh M, Asgari A, Abedi-Ardakani B, Tavangar SM, Khakinejad A et al. Silent Liver Diseases in Autopsies from Forensic Medicine of Tehran. *Archives of Iranian Medicine* 2006 Oct; 9(4):324-28.
9. Ghosh CK, Islam F, Ahmed E, Ghosh DK, Haque A, Islam QT et al. Etiological and Clinical Patterns of Isolated Hepatomegaly at Rajshahi, Bangladesh. *Euroasian Journal of Hepato-Gastroenterology*.2012 Jan-June;2(1):1-4.
10. Kringsholm B, Christoffersen P. Liver pathology in fatal drug addiction. *Forensic Science International* 1982 Sep-Oct; 20(2): 141-51.
11. Passarino G, Ciccone G, Siragusa R, Tappero P, Mollo F. Histopathological Findings in 851 Autopsies, with Toxicological and Virological Correlations. *American Journal of Forensic Medicine and Pathology* 2005 June; 26(2):106-16.
12. Daina CM, Daina LG, Bonta M, Rahotă DA, Muțiu GA. Study concerning the histopathological changes in chronic hepatopathies. *Romanian journal of morphology and embryology= Revue roumaine de morphologie et embryologie*. 2017 Jan 1;58(1):153-9.
13. Craig CE, Quaglia A, Selden C, Lowdell M, Hodgson H, Dhillon AP. The histopathology of regeneration in massive hepatic necrosis. *Semin Liver Dis*, 2004, 24(1):49–64.
14. Łapiński TW, Panasiuk A, Flisiak R, Wierzbička I. Liver biopsy: the mandatory test in liver diagnosis in adults. *Pol Merkur Lekarski*, 2001, 11(63):214–217.
15. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. *Hepatology*, 2004, 39(5):1230–1238.
16. Friedman SL. Hepatic fibrosis: emerging therapies. *Dig Dis*, 2015, 33(4):504–507.
17. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. *Gut*, 2015, 64(5):830–41.
18. Natarajan V, Harris EN, Kidambi S. SECs (sinusoidal endothelial cells), liver microenvironment, and fibrosis. *Biomed Res Int*, 2017:4097205.
19. Petrescu IO, Biciușcă V, Taisescu CI, Alexandru DO, Taisescu O, Comănescu MV, Petrescu F, Popescu IA, Trașcă DM, Forțoiu MC, Siloși CA, Forțoiu M. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. *Rom J Morphol Embryol*, 2016, 57(2 Suppl):759–765.

20. Efrem IC, Istrătoae O, Micu ES, Gheonea C, Lazăr DȘ, Firulescu SC, Predescu OI, Popescu NL. Anatomico-clinical correlations in hepatic steatosis in patients with C chronic hepatitis. *Rom J Morphol Embryol*, 2016, 57(2):513–519.
21. Ionică FE, Mogoantă L, Nicola GC, Chiriță C, Negreș S, Bejenaru C, Turculeanu A, Badea O, Popescu NL, Bejenaru LE. Antifibrotic action of telmisartan in experimental carbon tetrachloride-induced liver fibrosis in Wistar rats. *Rom J Morphol Embryol*, 2016, 57(4):1261–72.
22. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*, 2005, 115(2):209–218.
23. Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. *Korean J Intern Med*, 2017, 32(2):213–228.
24. Ueno T, Sata M, Sakata R, Torimura T, Sakamoto M, Sugawara H, Tanikawa K. Hepatic stellate cells and intralobular innervation in human liver cirrhosis. *Hum Pathol*, 1997, 28(8): 953–59.
25. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*, 2008, 134(6):1655–1669.
26. Pinzani M. Pathophysiology of liver fibrosis. *Dig Dis*, 2015, 33(4):492–497.
27. Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. *J Hepatol*, 2015, 63(4):1038–1039.

Source of Support: Nil. **Conflict of Interest:** None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Dhanraj Sarda. Histopathological Diagnosis amongst Subjects of Liver Diseases Reporting to the Pathology Department at a Tertiary Care Centre. *Int J Med Res Prof*. 2018 May; 4(3):250-53. DOI:10.21276/ijmrp.2018.4.3.053